- WuXi Biologics has signed a strategic Memorandum of Understanding with the Qatar Free Zones Authority to establish its first integrated CRDMO centre in the Middle East.
- The collaboration aims to support Qatar’s ambition to expand its biopharmaceutical sector and strengthen regional innovation.
WuXi Biologics has signed a Memorandum of Understanding (MoU) with the Qatar Free Zones Authority (QFZ) to expand its global Contract Research, Development and Manufacturing Organization network into the Middle East. The agreement was witnessed by government representatives including H.E. Sheikh Faisal bin Thani bin Faisal Al-Thani, Minister of Commerce and Industry and Chairman of QFZ.
The collaboration sets the foundation for WuXi Biologics to establish its first integrated CRDMO centre in the region. The partnership brings together the company’s one-stop CRDMO solutions, technologies and expertise in complex biologics with Qatar’s strategic objectives for biopharmaceutical sector growth. The planned development aligns with Qatar’s vision to strengthen innovation capacity and build a competitive biotechnology ecosystem.
According to the announcement, the MoU aims to support the advancement of biopharmaceutical capabilities in Qatar by leveraging WuXi Biologics’ experience in areas including bispecifics, multispecifics and antibody-drug conjugates. The integrated ecosystem within the free zones and Qatar’s regulatory and logistical infrastructure are intended to underpin the collaboration.
“This partnership is a pivotal step for WuXi Biologics. It marks the beginning of our journey in the region while extending our global network and capabilities.” He highlighted the potential to support clients in delivering treatments worldwide.
Dr Chris Chen, CEO of WuXi Biologics
QFZ CEO H.E. Sheikh Mohammed Bin Hamad Bin Faisal Al-Thani said the partnership would strengthen Qatar’s position as a reliable location for biopharmaceutical development and high-value manufacturing.
